< Back to latest news & events

Event

Seminar: Strategies and updates on patenting inventions relating to personalised medicine in Europe and the US – Basel

October 2019

Event date: 17th October 2019

HGF is hosting a seminar in Der Teufelhof Basel on Thursday 17th October at 6pm. Partner Dr Leena Contarino and Patent Director Dr Laurence Gainey will consider strategies for patenting inventions in Europe and the US.

Targeted intervention (also known as personalised medicine or precision medicine) is a rapidly evolving field of medicine in which treatments are selected based on the detection of disease markers in individual patients. This enables doctors to prescribe treatment regimens that are tailored to individual patients’ medical needs.

Targeted intervention is already well established modern oncology where new drugs are now often approved together with companion diagnostics used to identify particular markers or genetic mutations in a patient. It is likely that targeted intervention will also become a feature in other therapy areas as the technology evolves. Patenting and enforcing patents covering personalised medicine inventions can be challenging, most notably in the USA.

This seminar will consider strategies for patenting these inventions in Europe and the US, including an update on the evolving situation in the US such as: legislative efforts, USPTO updated guidance and recent court cases such as Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC (Fed. Cir. July 3, 2019).

To register please email ldavies@hgf.com.

Latest updates

The FoodTech Series #1 | Multi-parameter claims, examples outside the scope of the claims: when improvement occurs and evidence becomes easier to demonstrate

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article